(Q38183943)

30 August 2017

title

Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. (English)

1 reference

30 August 2017

1 reference

2

Carsten Müller-Tidow

0 references

author name string

Ruediger Liersch

series ordinal

1

1 reference

30 August 2017

Wolfgang E Berdel

series ordinal

3

1 reference

30 August 2017

Utz Krug

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

British Journal of Haematology

30 August 2017

published in

1 reference

30 August 2017

volume

165

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

17-38

1 reference

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

30 August 2017

cites work

1 reference

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene.

21 January 2018

1 reference

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

21 January 2018

1 reference

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review

21 January 2018

1 reference

CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.

21 January 2018

1 reference

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

21 January 2018

1 reference

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group

21 January 2018

1 reference

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

21 January 2018

1 reference

21 January 2018

1 reference

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

21 January 2018

1 reference

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

21 January 2018

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia

21 January 2018

1 reference

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

21 January 2018

1 reference

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia

21 January 2018

1 reference

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients

21 January 2018

1 reference

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

21 January 2018

1 reference

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

21 January 2018

1 reference

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

21 January 2018

1 reference

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

21 January 2018

1 reference

Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia

21 January 2018

1 reference

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

21 January 2018

1 reference

Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies

21 January 2018

1 reference

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

21 January 2018

1 reference

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

21 January 2018

1 reference

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

21 January 2018

1 reference

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

21 January 2018

1 reference

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

21 January 2018

1 reference

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival

21 January 2018

1 reference

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

21 January 2018

1 reference

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

21 January 2018

1 reference

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group

21 January 2018

1 reference

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

21 January 2018

1 reference

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia

21 January 2018

1 reference

Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias

21 January 2018

1 reference

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

21 January 2018

1 reference

MicroRNAs in myeloid malignancies.

21 January 2018

1 reference

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations

21 January 2018

1 reference

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

21 January 2018

1 reference

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

21 January 2018

1 reference

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

21 January 2018

1 reference

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

21 January 2018

1 reference

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

21 January 2018

1 reference

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

21 January 2018

1 reference

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

21 January 2018

1 reference

CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).

21 January 2018

1 reference

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

21 January 2018

1 reference

Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

21 January 2018

1 reference

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

21 January 2018

1 reference

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

21 January 2018

1 reference

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

21 January 2018

1 reference

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

21 January 2018

1 reference

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

21 January 2018

1 reference

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

21 January 2018

1 reference

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study

21 January 2018

1 reference

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

21 January 2018

1 reference

CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.

21 January 2018

1 reference

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

21 January 2018

1 reference

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

21 January 2018

1 reference

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

21 January 2018

1 reference

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

21 January 2018

1 reference

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients

21 January 2018

1 reference

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

21 January 2018

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

21 January 2018

1 reference

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

21 January 2018

1 reference

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia

21 January 2018

1 reference

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia

21 January 2018

1 reference

Gene mutations of acute myeloid leukemia in the genome era.

21 January 2018

1 reference

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

21 January 2018

1 reference

Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor

21 January 2018

1 reference

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

21 January 2018

1 reference

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

21 January 2018

1 reference

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

21 January 2018

1 reference

CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis.

21 January 2018

1 reference

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

21 January 2018

1 reference

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

21 January 2018

1 reference

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

21 January 2018

1 reference

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

21 January 2018

1 reference

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia

21 January 2018

1 reference

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

21 January 2018

1 reference

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

21 January 2018

1 reference

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

21 January 2018

1 reference

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

21 January 2018

1 reference

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

21 January 2018

1 reference

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

21 January 2018

1 reference

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

21 January 2018

1 reference

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

21 January 2018

1 reference

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

21 January 2018

1 reference

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

21 January 2018

1 reference

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia

21 January 2018

1 reference

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

21 January 2018

1 reference

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

21 January 2018

1 reference

High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.

21 January 2018

1 reference

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.

21 January 2018

1 reference

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

21 January 2018

1 reference

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

21 January 2018

1 reference

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

21 January 2018

1 reference

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients

21 January 2018

1 reference

Prognostically useful gene-expression profiles in acute myeloid leukemia.

21 January 2018

1 reference

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

21 January 2018

1 reference

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

21 January 2018

1 reference

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies

21 January 2018

1 reference

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

21 January 2018

1 reference

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

21 January 2018

1 reference

Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.

21 January 2018

1 reference

Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

21 January 2018

1 reference

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12750

1 reference

30 August 2017

1 reference